Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Laboratory Corporation of America Holdings is a diagnostics & research business based in the US. Laboratory Corporation of America shares (LH) are listed on the NYSE and all prices are listed in US Dollars. Laboratory Corporation of America employs 70,000 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $271.57 |
|---|---|
| 52-week range | $212.85 - $317.17 |
| 50-day moving average | $292.38 |
| 200-day moving average | $282.59 |
| Wall St. target price | $341.71 |
| PE ratio | 9.7946 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $28.19 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $271.57 from 2022-01-21
| 1 week (2022-01-14) | -1.63% |
|---|---|
| 1 month (2021-12-22) | -10.73% |
| 3 months (2021-10-22) | -3.75% |
| 6 months (2021-07-22) | -3.39% |
| 1 year (2021-01-22) | 18.64% |
|---|---|
| 2 years (2020-01-22) | 51.24% |
| 3 years (2019-01-22) | 100.13% |
| 5 years (2017-01-20) | 105.11% |
Valuing Laboratory Corporation of America stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Laboratory Corporation of America's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Laboratory Corporation of America's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, Laboratory Corporation of America shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Laboratory Corporation of America's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0681. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Laboratory Corporation of America's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Laboratory Corporation of America's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.6 billion.
The EBITDA is a measure of a Laboratory Corporation of America's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $16.6 billion |
|---|---|
| Operating margin TTM | 24.76% |
| Gross profit TTM | $5 billion |
| Return on assets TTM | 12.94% |
| Return on equity TTM | 29.4% |
| Profit margin | 16.69% |
| Book value | $109.86 |
| Market capitalisation | $26.4 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Laboratory Corporation of America.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 19.26
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Laboratory Corporation of America's overall score of 19.26 (as at 12/31/2018) is excellent – landing it in it in the 15th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Laboratory Corporation of America is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.17/100
Laboratory Corporation of America's environmental score of 4.17 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Laboratory Corporation of America is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 11.07/100
Laboratory Corporation of America's social score of 11.07 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Laboratory Corporation of America is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.02/100
Laboratory Corporation of America's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Laboratory Corporation of America is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Laboratory Corporation of America scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Laboratory Corporation of America has, for the most part, managed to keep its nose clean.
Laboratory Corporation of America Holdings was last rated for ESG on: 2019-01-01.
| Total ESG score | 19.26 |
|---|---|
| Total ESG percentile | 14.56 |
| Environmental score | 4.17 |
| Environmental score percentile | 7 |
| Social score | 11.07 |
| Social score percentile | 7 |
| Governance score | 13.02 |
| Governance score percentile | 7 |
| Level of controversy | 2 |
We're not expecting Laboratory Corporation of America to pay a dividend over the next 12 months.
Laboratory Corporation of America's shares were split on a 2:1 basis on 12 May 2002. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Laboratory Corporation of America shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Laboratory Corporation of America shares which in turn could have impacted Laboratory Corporation of America's share price.
Over the last 12 months, Laboratory Corporation of America's shares have ranged in value from as little as $212.85 up to $317.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Laboratory Corporation of America's is 1.0258. This would suggest that Laboratory Corporation of America's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company has a collaboration agreement with community clinical oncology research network, LLC to understand the impact of disparities in precision medicine for people with cancer; and strategic collaboration with GeneCentric Therapeutics, Inc.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
